<DOC>
	<DOCNO>NCT00887458</DOCNO>
	<brief_summary>This research do test investigational drug , call itraconazole , treatment prostate cancer . Itraconazole approve Food Drug Administration ( FDA ) treatment various fungal infection fingernail/toenail infection serious fungal infection . The word `` investigational '' mean itraconazole approve use people cancer . However , FDA allow use itraconazole research study . Itraconazole show activity cancer ( include prostate cancer ) laboratory , test cancer human . The purpose study find : - If itraconazole safe give two different dos - How itraconazole affect prostate specific antigen ( PSA ) : blood test measure substance release prostate cancer - Whether itraconazole delay prostate cancer growth spread - How itraconazole affect marker prostate cancer</brief_summary>
	<brief_title>A Two-dose Level Clinical Trial Itraconazole Patients With Metastatic Prostate Cancer Who Have Had Disease Progression While Hormonal Therapy</brief_title>
	<detailed_description>Itraconazole oral , generic , commercially available antifungal drug long safety record use dos range 200 600 mg daily . Itraconazole show cellular animal model potent angiogenesis inhibitor well Hedgehog pathway antagonist ; pathway consider important prostate cancer . Itraconazole previously test antineoplastic agent , give well-established safety profile , gap preclinical study human clinical trial narrow accelerate development agent putative anticancer drug . We hypothesize itraconazole prevent PSA progression significant proportion men metastatic CRPC acceptable safety profile dos . Itraconazole may ultimately delay need chemotherapy men .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Histologically cytologically confirm prostate adenocarcinoma . Presence distant metastasis bone scan , CT scan , MRI scan . Progression androgen deprivation ( antiandrogen withdrawal ) . Rising serum PSA ( Prostate Cancer Working Group ( PCWG2 ) definition ) . Castrate level serum testosterone ( i.e. , ≤ 50 ng/dL ) . Age &gt; 18 year . ECOG performance status score ≤ 2 , and/or Karnofsky score ≥ 50 % . Life expectancy &gt; 6 month . Adequate kidney , liver , bone marrow function . Willingness sign inform consent adhere study requirement . Recent surgery , radiation therapy , combine androgen blockade , investigational therapy last 8 week . Previous chemotherapy metastatic prostate cancer . Concomitant use secondline hormonal agent ( e.g. , ketoconazole , DES ) Current use corticosteroid , except stable dose ≥ 3 month . History malabsorption syndrome ( may affect itraconazole absorption ) . Allergic reaction itraconazole similar compound . Concurrent use drug interact CYP3A4 system ( caution ) . Presence known brain metastasis . Prior malignancy last 3 year , exception . Uncontrolled major infectious , cardiac , pulmonary illness . Prolonged correct QT interval ( &gt; 450 msec ) electrocardiography .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>metastatic prostate cancer</keyword>
	<keyword>castration resistant prostate cancer</keyword>
	<keyword>rise PSA</keyword>
</DOC>